A Phase 4 interventional study of Deucravacitinib and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.
Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 4, and was the 14th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in Argentina, Australia, Brazil and 10 more countries
Ages 4–18
Bristol-Myers Squibb
Ages 4–75
By country, each count listing its studies:
deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 10 · Phase 4 8
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 102 across the 26 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Psoriasis by Bristol-Myers Squibb: 9 open now, 14 under way, 4 of them phase 3. Of 28 finished, 10 (36%) have results posted.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 4, and was the 24th registered.
Bristol-Myers Squibb’s Psoriasis studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing deucravacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Target Disease Exceptions:
Drug: Deucravacitinib
Drug: Deucravacitinib · Other: Placebo
Specified dose on specified days
Also known as: BMS-986165
Specified dose on specified days
Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16
ss-PGA 0/1 response as a percentage of participants with an ss-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. Scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.
Time frame: Baseline and Week 16
Percentage of Participants With a Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16
PSSI 90 response as a percentage of participants who achieve at least 90% improvement from baseline in the PSSI score at Week 16. PSSI assesses severity of scalp disease in participants with scalp involvement with a 5-point Likert-type scale on the clinical parameters of erythema, induration, and desquamation. The scores are summed and multiplied by an integer (0 to 6) that represents the area of affected scalp. The PSSI score ranges from 0 to 72 with higher scores indicating more severe symptoms.
Time frame: Baseline and Week 16
Change From Baseline in Scalp-specific Itch Numerical Rating Scale (NRS) Score at Week 16
Change from baseline in scalp-specific itch numerical rating scale (NRS) score at week 16. The scalp-specific itch NRS is an 11-point horizontal scale anchored at 0 and 10 with 0 representing "no scalp itch" and 10 representing "worst scalp itch imaginable.". Overall severity of a participant's itching from scalp psoriasis is indicated by selecting the number that best describes the worst level of scalp itching within the past 24 hours.
Time frame: Baseline and Week 16
Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16
s-PGA 0/1 response as a percentage of participants with an s-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. The s-PGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The s-PGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).
Time frame: Baseline and Week 16
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment.
Time frame: From week 0 through week 16
Number of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From week 0 through week 16
Number of Participants Experiencing Laboratory Test Results of Worst Toxicity Grade
Laboratory test results summary of Worst toxicity grade in SI units for hematology and chemistry using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1= mild and asymptomatic; Grade 2= moderate requiring minimal, local or noninvasive intervention; Grade 3= severe or medically significant but not immediately life-threatening; Grade 4= events are usually severe enough to require hospitalization.
Time frame: Week 0 through Week 16
Number of Participants Experiencing Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests
Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=alanine aminotransferase AST=aspartate aminotransferase ULN=upper limit of normal
Time frame: Week 0 through Week 16
Number of Participants With Abnormalities in Vital Signs
Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.
Time frame: Week 0 through Week 16
| Milestone | Deucravacitinib | Placebo |
|---|---|---|
| Started | 103 | 51 |
| Completed | 94 | 45 |
| Not completed | 9 | 6 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other reasons | 0 | 2 |
| Milestone | Deucravacitinib | Placebo |
|---|---|---|
| Started | 94 | 45 |
| Completed | 80 | 39 |
| Not completed | 14 | 6 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Lack of efficacy | 4 | 1 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Non-compliance with protocol | 0 | 1 |
ss-PGA 0/1 response as a percentage of participants with an ss-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. Scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.
| Percentage of responders | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | 48.5 (38.6 to 58.6) | 13.7 (5.7 to 26.3) |
| Patient sub-population (s-PGA ≥ 3) | 50.0 (39.6 to 60.4) | 12.8 (4.8 to 25.7) |
PSSI 90 response as a percentage of participants who achieve at least 90% improvement from baseline in the PSSI score at Week 16. PSSI assesses severity of scalp disease in participants with scalp involvement with a 5-point Likert-type scale on the clinical parameters of erythema, induration, and desquamation. The scores are summed and multiplied by an integer (0 to 6) that represents the area of affected scalp. The PSSI score ranges from 0 to 72 with higher scores indicating more severe symptoms.
| Percentage of responders | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | 38.8 (29.4 to 48.9) | 2.0 (NA to 10.4) |
| Patient sub-population (s-PGA ≥ 3) | 40.6 (30.7 to 51.1) | 2.1 (NA to 11.3) |
Change from baseline in scalp-specific itch numerical rating scale (NRS) score at week 16. The scalp-specific itch NRS is an 11-point horizontal scale anchored at 0 and 10 with 0 representing "no scalp itch" and 10 representing "worst scalp itch imaginable.". Overall severity of a participant's itching from scalp psoriasis is indicated by selecting the number that best describes the worst level of scalp itching within the past 24 hours.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | -3.2 ± 2.95 | -0.7 ± 2.27 |
| Patient sub-population (s-PGA ≥ 3) | -3.3 ± 2.87 | -0.9 ± 2.29 |
s-PGA 0/1 response as a percentage of participants with an s-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. The s-PGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The s-PGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).
| Percentage of responders | Deucravacitinib | Placebo |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16 | 51.0 (40.6 to 61.4) | 4.3 (0.5 to 14.5) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 73 | 26 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs) | 1 | 1 |
Laboratory test results summary of Worst toxicity grade in SI units for hematology and chemistry using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1= mild and asymptomatic; Grade 2= moderate requiring minimal, local or noninvasive intervention; Grade 3= severe or medically significant but not immediately life-threatening; Grade 4= events are usually severe enough to require hospitalization.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Basophils (10^9/L) Grade 1-4 | 0 | 0 |
| Eosinophils (10^9/L) Grade 1 | 4 | 2 |
| Eosinophils (10^9/L) Grade 2-4 | 0 | 0 |
| Hemoglobin (g/L) Grade 1 | 5 | 4 |
| Hemoglobin (g/L) Grade 2 | 1 | 0 |
| Hemoglobin (g/L) Grade 3 | 0 | 0 |
| Leukocytes (10^9/L) Grade 1 | 8 | 1 |
| Leukocytes (10^9/L) Grade 2 | 0 | 1 |
| Leukocytes (10^9/L) Grade 3-4 | 0 | 0 |
| Lymphocytes Blood Test (10^9/L) Grade 1 | 1 | 1 |
| Lymphocytes Blood Test (10^9/L) Grade 2 | 1 | 0 |
| Lymphocytes Blood Test (10^9/L) Grade 3-4 | 0 | 0 |
| Lymphocytes Plasma Test (10^9/L) Grade 1 | 1 | 1 |
| Lymphocytes Plasma Test (10^9/L) Grade 2 | 1 | 0 |
| Lymphocytes Plasma Test (10^9/L) Grade 3-4 | 0 | 0 |
| Neutrophils (x10^9/L) Grade 1 | 5 | 2 |
| Neutrophils (x10^9/L) Grade 2-4 | 0 | 0 |
| Platelets (10^9/L) Grade 1-4 | 0 | 0 |
| Alanine Aminotransferase (U/L) Grade 1 | 8 | 8 |
| Alanine Aminotransferase (U/L) Grade 2 | 0 | 1 |
| Alanine Aminotransferase (U/L) Grade 3-4 | 0 | 0 |
| Albumin (g/L) Grade 1-4 | 0 | 0 |
| Alkaline Phosphatase (U/L) Grade 1 | 1 | 2 |
| Alkaline Phosphatase (U/L) Grade 2-4 | 0 | 0 |
| Aspartate Aminotransferase (U/L) Grade 1 | 5 | 5 |
| Aspartate Aminotransferase (U/L) Grade 2-4 | 0 | 0 |
| Bilirubin (umol/L) Grade 1 | 5 | 3 |
| Bilirubin (umol/L) Grade 2 | 1 | 0 |
| Bilirubin (umol/L) Grade 3-4 | 0 | 0 |
| Calcium (mmol/L) Grade 1 | 1 | 0 |
| Calcium (mmol/L) Grade 2-4 | 0 | 0 |
| Chloride (mmol/L) Grade 1-4 | 0 | 0 |
| Cholesterol (mmol/L) Grade 1 | 5 | 0 |
| Cholesterol (mmol/L) Grade 2-4 | 0 | 0 |
| Creatine Kinase (U/L) Grade 1-4 | 0 | — |
| Creatinine (umol/L) Grade 1 | 3 | 0 |
| Creatinine (umol/L) Grade 2 | 1 | 0 |
| Creatinine (umol/L) Grade 3-4 | 0 | 0 |
| Direct Bilirubin (umol/L) Grade 1-4 | 0 | 0 |
| Glucose (mmol/L) Grade 1 | 2 | 0 |
| Glucose (mmol/L) Grade 2-4 | 0 | 0 |
| Lactate Dehydrogenase (U/L) Grade 1-4 | 0 | — |
| Magnesium (mmol/L) Grade 1-4 | 0 | — |
| Phosphate (mmol/L) Grade 1-4 | 0 | 0 |
| Potassium (mmol/L) Grade 1 | 6 | 2 |
| Potassium (mmol/L) Grade 2 | 8 | 1 |
| Potassium (mmol/L) Grade 3 | 0 | 1 |
| Potassium (mmol/L) Grade 4 | 0 | 0 |
| Sodium (mmol/L) Grade 1 | 0 | 2 |
| Sodium (mmol/L) Grade 2 | 1 | 0 |
| Sodium (mmol/L) Grade 3-4 | 0 | 0 |
| Triglycerides (mmol/L) Grade 1 | 27 | 7 |
| Triglycerides (mmol/L) Grade 2 | 2 | 3 |
| Triglycerides (mmol/L) Grade 3 | 1 | 0 |
| Triglycerides (mmol/L) Grade 4 | 0 | 1 |
| Urate (umol/L) Grade 1-4 | 0 | — |
| Urea Nitrogen (mmol/L) Grade 1-4 | 0 | 0 |
Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=alanine aminotransferase AST=aspartate aminotransferase ULN=upper limit of normal
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| ALT or AST > 3 X ULN | 0 | 1 |
| ALT or AST > 5 X ULN | 0 | 0 |
| Total Bilirubin > 2 X ULN | 0 | 0 |
| ALT or AST > 3 X ULN and total bilirubin > 2 X ULN on the same day | 0 | 0 |
Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| HEART RATE (BEATS/MIN): VALUE > 100 AND CHANGE FROM BASELINE > 30 | 0 | 0 |
| HEART RATE (BEATS/MIN): VALUE < 55 AND CHANGE FROM BASELINE < -15 | 1 | 3 |
| HEART RATE (BEATS/MIN): NOT REPORTED | 0 | 0 |
| SYSTOLIC BLOOD PRESSURE (MMHG): VALUE > 140 AND CHANGE FROM BASELINE > 20 | 3 | 4 |
| SYSTOLIC BLOOD PRESSURE (MMHG): VALUE < 90 AND CHANGE FROM BASELINE < -20 | 0 | 0 |
| SYSTOLIC BLOOD PRESSURE (MMHG): NOT REPORTED | 0 | 0 |
| DIASTOLIC BLOOD PRESSURE (MMHG): VALUE > 90 AND CHANGE FROM BASELINE > 10 | 8 | 3 |
| DIASTOLIC BLOOD PRESSURE (MMHG): VALUE < 55 AND CHANGE FROM BASELINE < -10 | 0 | 2 |
| DIASTOLIC BLOOD PRESSURE (MMHG): NOT REPORTED | 0 | 0 |
Collected over Participants were assessed for all-cause mortality from their first dose to their primary data cut-off (Up to 24 months). SAEs and Other AEs were assessed from first dose up to 30 days post last dose (Up to 13 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Controlled - Deucravacitinib | 0/103 (0%) | 1/103 (1%) | 47/103 (45.6%) |
| Placebo Controlled - Placebo | 0/51 (0%) | 1/51 (2%) | 14/51 (27.5%) |
| Active Treatment - Deucravacitinib - Deucravacitinib | 1/94 (1.1%) | 4/94 (4.3%) | 42/94 (44.7%) |
| Active Treatment - Placebo - Deucravacitinib | 0/45 (0%) | 0/45 (0%) | 16/45 (35.6%) |
| Event | Placebo Controlled - Deucravacitinib | Placebo Controlled - Placebo | Active Treatment - Deucravacitinib - Deucravacitinib | Active Treatment - Placebo - Deucravacitinib |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/103 | 1/51 | 0/94 | 0/45 |
| Myocardial infarctionCardiac disorders | 0/103 | 0/51 | 1/94 | 0/45 |
| Ligament disorderMusculoskeletal and connective tissue disorders | 0/103 | 0/51 | 1/94 | 0/45 |
| Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/103 | 0/51 | 1/94 | 0/45 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/103 | 0/51 | 1/94 | 0/45 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/103 | 0/51 | 0/94 | 0/45 |
| Event | Placebo Controlled - Deucravacitinib | Placebo Controlled - Placebo | Active Treatment - Deucravacitinib - Deucravacitinib | Active Treatment - Placebo - Deucravacitinib |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 16/103 | 7/51 | 22/94 | 8/45 |
| COVID-19Infections and infestations | 6/103 | 4/51 | 12/94 | 4/45 |
| Upper respiratory tract infectionInfections and infestations | 12/103 | 2/51 | 11/94 | 3/45 |
| AcneSkin and subcutaneous tissue disorders | 10/103 | 0/51 | 1/94 | 1/45 |
| HeadacheNervous system disorders | 8/103 | 2/51 | 2/94 | 1/45 |
| PsoriasisSkin and subcutaneous tissue disorders | 2/103 | 3/51 | 4/94 | 0/45 |
| Acne pustularInfections and infestations | 6/103 | 0/51 | 3/94 | 0/45 |
| Age, Continuous(Years) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Mean | 42.8 ± 15.70 | 43.2 ± 13.08 | 42.9 ± 14.84 |
| Sex: Female, Male(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Female | 45 | 20 | 65 |
| Male | 58 | 31 | 89 |
| Ethnicity (NIH/OMB)(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 95 | 43 | 138 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 2 | 5 |
| Black or African American | 5 | 2 | 7 |
| Native Hawaiian or other pacific islander | 0 | 0 | 0 |
| White | 93 | 47 | 140 |
| Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2022 to primary completion in Jan 2024, 15 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 15 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib